To avoid misinterpretation and mismanagement clinicians should be aware of the
interference of new direct oral anticoagulants (DOA) on coagulation assays. A variety of oral …

Introduction Different coagulation indices for direct oral anticoagulants (DOACs) exist in
clinical practice, but limited data are available for the diagnostic power of these indices. This …

Aim: Novel oral anticoagulants are characterized by a wide therapeutic window, yet the
determination of their plasma–drug concentrations may be useful in some clinical …

Although the direct oral anticoagulants (DOACs) do not require routine monitoring and
reduce bleeding compared with warfarin, there are special circumstances in which …

Warfarin is still the most used oral anticoagulant; in Italy approximately 650,000 subjects
were taking warfarin in 2006 with an annual increase of 5%[1]. The main drawback of …

New oral anticoagulants like the direct thrombin inhibitor, dabigatran (P radaxa®), and factor
X a‐inhibitors, rivaroxaban (X arelto®) and apixaban (E liquis®) are available for …

Dabigatran, rivaroxaban, and apixaban are direct oral anticoagulants (DOAC) inhibiting
thrombin or factor Xa and effectively preventing thromboembolic complications using fixed …

Several new oral anticoagulants such as rivaroxaban (which targets Factor Xa) and
dabigatran etexilate (which targets thrombin) are in advanced stages of clinical development …

Introduction: For years, anticoagulants have been the basic group of drugs that slow down,
inhibit or prevent blood clotting by inhibiting thrombin formation or reducing its activity …

The effect of direct oral anticoagulants (DOACs) on laboratory tests dependent on the
production of their targets, factor IIa and factor Xa (FXa), is a well-known problem and can …